|1.||Spinowitz, Bruce S: 3 articles (01/2009 - 12/2006)|
|2.||Pratt, Raymond D: 3 articles (07/2007 - 12/2006)|
|3.||Kwan, Jonathan T C: 2 articles (01/2009 - 02/2007)|
|4.||Dowell, James A: 2 articles (07/2008 - 07/2007)|
|5.||Hammes, H P: 1 article (06/2010)|
|6.||Feng, Y: 1 article (06/2010)|
|7.||Lin, J: 1 article (06/2010)|
|8.||Pfister, F: 1 article (06/2010)|
|9.||vom Hagen, F: 1 article (06/2010)|
|10.||Wang, Q: 1 article (06/2010)|
|1.||Kidney Diseases (Kidney Disease)
01/01/2007 - "Previous clinical trials have shown that the only human cell-line-derived ESA, epoetin delta, is well tolerated and effective in maintaining haemoglobin levels in anaemic patients with chronic kidney disease. "
12/01/2006 - "Epoetin delta is effective for the management of anaemia associated with chronic kidney disease."
02/01/2007 - "To demonstrate safety and efficacy of epoetin delta for the management of anaemia in predialysis patients with chronic kidney disease (CKD). "
07/01/2007 - "The pharmacokinetics of epoetin delta were examined in 2 studies in healthy volunteers and 2 studies in patients with chronic kidney disease. "
07/01/2007 - "Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease."
07/01/2007 - "The only adverse event occurring in > or = 10% of healthy individuals in study 1 was headache (1 [20.0%] in the epoetin delta 15 IU-kg group, 3 [60.0%] in the epoetin delta 100-IU/kg group, 2 [33.3%] in the placebo group). "
07/01/2007 - "The only adverse event occurring in > or = 10% of subjects was headache (2 [40.0%] in the epoetin delta 150-IU/kg IV group, 3 [50.0%] in the epoetin delta 300-IU/kg SC group). "
12/15/2008 - "Epoetin delta is engineered in cultures of the human fibrosarcoma cell line HT-1080 by homologous recombination and "gene activation." Unlike recombinant erythropoietins produced in other mammalian cells, epoetin delta is supposed to have a human-type glycosylation profile. "
01/01/2007 - "Gene-activated EPO (epoetin delta [delta]) from human fibrosarcoma cells (HT-1080) has recently been launched for use in CKD. "
01/01/2009 - "Epoetin delta is special, as it was engineered by homologous recombination in human fibrosarcoma cells (HT-1080), thus lacking N-glycolylneuraminic acid like native human EPO. "
11/01/2008 - "Double-blind study: 313 cancer patients were randomised to epoetin delta or placebo. "
11/01/2008 - "Epoetin delta shows potential as a treatment for anaemia in cancer patients receiving chemotherapy."
11/01/2008 - "To assess the effect of epoetin delta on anaemia in patients with cancer who were receiving chemotherapy. "
11/01/2008 - "Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy."
12/15/2008 - "Recently, a novel recombinant human erythropoietin (epoetin delta, Dynepo) has been marketed in the European Union for the treatment of chronic kidney disease, cancer patients receiving chemotherapy, and so forth. "
|3.||Epoetin Alfa (Epogen)
|2.||Drug Therapy (Chemotherapy)